BOARD OF DIRECTORS
Ansbert Gadicke, MD
MPM Capital, TCR² Chairman of the Board
Dr. Gadicke is co-founder and Managing Director of MPM Capital and its venture capital activities as well as an investment committee member of its oncology-only crossover investment strategy (both public and private equities). Dr. Gadicke led the company-building efforts of several of MPM’s most successful investments including BioMarin Pharmaceuticals, Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), Pharmasset (acquired by Gilead Sciences) and Radius Health – companies that are helping thousands of patients live longer and vastly improved lives. Sovaldi, developed by Pharmasset, was the first cure for Hepatitis C and experienced the most successful product launch in the pharmaceutical industry. Prior to founding MPM, Dr. Gadicke was at The Boston Consulting Group. Dr. Gadicke, active in guiding MPM portfolio companies, also serves as Chairman of the Board at Cullinan Oncology and is a member of the Board of ElevateBio and iTeos Therapeutics. He is also a member of the Board of Fellows of Harvard Medical School and the Research Advisory Council of the Massachusetts General Hospital. He received an MD from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University. While at the German Cancer Research Center, he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.
Andrew Allen, M.D., Ph.D. Gritstone Oncology
Dr. Allen is a co-founder of Gritstone Oncology, Inc. (NASDAQ:GRTS), and has served as its President, Chief Executive Officer and a board member since its inception in August 2015. Prior to Gritstone, in April 2009, Dr. Allen co-founded Clovis Oncology, Inc., or Clovis, a public pharmaceutical development company, and served as its executive vice president of clinical and preclinical development and chief medical officer from April 2009 to July 2015. Prior to that, he was chief medical officer at Pharmion Corporation from 2006 to 2008 (acquired by Celgene for $2.9B). Previously, Dr. Allen served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company, where he advised life science companies on strategic issues. He currently serves on the board of directors of Epizyme, Inc., and Sierra Oncology, Inc., both public biopharmaceutical companies, and Revitope Oncology, Inc, a private biotechnology company. Dr. Allen previously served on the board of directors of Cell Design Labs, a private biotechnology company, from November 2015 until its acquisition by Gilead Sciences, Inc. in December 2017. Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from Imperial College of Science, Technology and Medicine in London.
Patrick Baeuerle, PhD
MPM Capital, TCR² Founder
Dr. Baeuerle is a Managing Director of MPM Capital and Founder of TCR². Prior to joining MPM, he served as Vice President, Research, and General Manager at Amgen Research (Munich) GmbH where he pioneered the development of the BiTE technology and spearheaded the development of Blincyto®, a bispecific T cell-engaging antibody which received accelerated FDA approval for the treatment of relapsed/refractory ALL. He worked for the last 18 years on pharmaceutical strategies for engaging patient T cells for cancer therapy. From 1998-2012, Dr. Baeuerle served as Chief Scientific Officer for Micromet, and earlier oversaw drug discovery at Tularik. He also served as Professor and Chairman of Biochemistry and Molecular Biology at the Medical Faculty of Freiburg University, Germany, and conducted seminal research on transcription factor NF-kappaB. Dr. Baeuerle was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990-1997), with more than 230 publications to date. He holds a PhD in biology from the University of Munich, and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute in Cambridge, MA. He is also an Honorary Professor of Immunology of the Medical Faculty at Munich University.
Mitchell (Mitch) Finer, PhD
Dr. Finer is a Managing Director of MPM Capital. Dr. Finer also serves on the boards of directors of Adverum Biotechnologies, Inc., Semma Therapeutics, Inc., Oncorus, Inc. and CODA Biotherapeutics, Inc. For three decades, Dr. Finer has focused on utilizing novel platforms of cell and gene therapy, cancer immunotherapy and regenerative medicine to develop products from conception through phase III clinical studies. Prior to MPM, Dr. Finer served as Chief Scientific Officer of bluebird bio where he was responsible for strategic build of its gene-modified adult hematopoietic stem cell therapy business and led the strategic development and partnering of its CAR-T and genome engineering programs. Prior to bluebird bio, Dr. Finer served as CEO of Intracel Corporation and Genteric Inc, VP Research for Cell Genesys and the Gencell division of Aventis Pharma (now Sanofi) and SVP of Development at Novacell (now Viacyte). Dr. Finer also founded Oncorus Inc., focused on oncolytic herpes viruses for the treatment of GBM and other malignancies, and co-founded both Coda Biotherapeutics and Avalanche Biotechnologies (now Adverum Biotechnologies). Dr. Finer received his PhD in Biochemistry and Molecular Biology from Harvard University and completed a post-doctoral fellowship at the Whitehead Institute for Biomedical Research at MIT.
Neil W. Gibson, PhD
Dr. Gibson is Chief Scientific Officer of COI Pharmaceuticals. In this role, he is responsible for the creation of new biotechnology companies that advance innovative therapeutics into areas of high unmet medical need. He is currently serving as CEO for Adanate and Chief Scientific Officer for PDI Therapeutics and Silarus Therapeutics. Dr. Gibson has more than 30 years of drug development experience and has been involved in the successful discovery, development and commercialization of four approved oncology drugs (temozolomide, sorafenib, erlotnib, and crizotinib). Dr. Gibson has held numerous senior positions within the biotechnology and pharmaceutical industry, including Chief Scientific Officer of Regulus Therapeutics, Chief Scientific Officer and Oncology Therapeutic Area Head at Pfizer Oncology, and Chief Scientific Officer at OSI Pharmaceuticals. Dr. Gibson has also held numerous academic appointments, including Associate Professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. During his career, Dr. Gibson has served on the Experimental Therapeutics Study Section of the National Cancer Institute. Dr. Gibson earned his Ph.D. in 1982 from the University of Aston.
Garry Menzel, PhD and MBA
TCR² President and Chief Executive Officer
Dr. Menzel joined TCR² in 2016 as a Director and Chief Executive Officer. He has over 25 years of experience in building healthcare businesses and leading high-performing teams of professionals. His versatile career has included operational roles covering drug development, manufacturing, financing, licensing and M&A. Prior to TCR², he was the Chief Strategy Officer at Axcella Health, the Chief Financial Officer at DaVita Healthcare (NYSE: DVA), and the Chief Operating Officer at Regulus Therapeutics (NASDAQ:RGLS). Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs and Credit Suisse where he advised on more than $100 billion in strategic transactions. In addition, he was a consultant with Bain & Company. Dr. Menzel has also served on the board of directors of the oncology company Black Diamond Therapeutics Inc. since 2014. He earned his PhD from the University of Cambridge for studying the regulation of oncogenes in immune cells. He also has a MBA from the Stanford Graduate School of Business.
Mitchell (Mitch) Finer, PhD
TCR² Chairman of the Advisory Board
Member of TCR² Board of Directors
Managing Director, MPM Capital, Cambridge, MA
Board of Directors Member – Adverum Biotechnologies, Semma Therapeutics, Oncorus, and CODA Biotherapeutics
Cell therapy manufacturing expert: Developed bluebird bio’s strategy as CSO from 2010-2015
Stephan Grupp, MD and PhD
Yetta Deitch Novotny Professor of Pediatrics, Perelman School of Medicine, University of Pennsylvania
Chief of the Section of Cellular Therapy and Transplant, Children’s Hospital of Philadelphia, PA
CAR-T development pioneer: Treated Emily Whitehead, the first pediatric patient to receive CAR-T therapy
Marcela Maus, MD and PhD
Assistant Professor of Medicine, Harvard Medical School
Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital, Boston, MA
Leading CAR-T and cancer immunotherapy researcher: Leads the Cellular Immunotherapy program at the MGH Cancer Center
Wolfgang Schamel, PhD
Professor and Chairman, Institute of Biology III (Molecular Immunology) and Centre for
Biological Signaling Studies (BIOSS), University of Freiburg, Germany
Leading researcher on T-cell receptor signaling: Studies TCR structure, subunit function, and downstream signaling
Kai Wucherpfennig, MD and PhD
Professor and Chairman, Department of Cancer Immunology and
Virology Director of Center for Cancer Immunotherapy Research, Boston, MA
Prominent T-cell biologist and cancer immunologist: Researches T-cell regulation and the tumor microenvironment’s effect on T-cells